Akums Drugs and Pharmaceuticals Ltd Q1 FY26 Results
AKUMSQ1 FY26 ResultsAnnounced 8 Aug 2025, 05:24 pm| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 1.0K | 3.0% |
| Total Income | 1.1K | 2.1% |
| Expenditure | 955.12 | 5.1% |
| PBT | 95.65 | 27.3% |
| Net Profit | 64.69 | 56.8% |
| OPM | 12.59% | 2.91pp |
| NPM | 6.16% | 7.78pp |
| EPS | 4.15 | 57.0% |
Akums Reports Q1 FY26 with 19% YoY Adj EBITDA Growth; Achieves 1,000 DCGI Approvals
08 Aug 2025 · 8 Aug 2025, 06:08 pm
Summary
Akums Drugs and Pharmaceuticals Limited, largest India-focused contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter ended June 30, 2025. The company reported total income of <1,051 crore, with healthy Adj EBITDA of 156 crore reflecting a robust 19.1% year-on-year (YoY) growth. The company achieved a key milestone of reaching 1,000 Drug Controller General of India (DCGI) approvals and received its first European dossier approval for Rivaroxaban.
Key Highlights
- 1
Q1 FY26 with 19% YoY Adj EBITDA growth
- 2
Achieved 1,000 DCGI approvals
- 3
Received first European dossier approval for Rivaroxaban
- 4
Flagship business, CDMO, contributed ~79% to the group turnover with an EBITDA of 14.7% in Q1 FY 26
- 5
Domestic branded formulation business reported ~3% YoY growth
- 6
International branded formulation business grew by ~2% YoY
- 7
Trade generics and API segment continue to be in operational loss
- 8
Cash surplus of =1,518 crore
Management Comments
Mr. Sanjeev Jain
Managing Director
This date marks just over one year since we got listed. We continue to work towards strengthening the organization with a focus on long term growth. Our commitment to becoming a global CDMO player remains steadfast. The recent filings along with the planned global approvals of other facilities are setting up us in that endeavor.
Mr. Sandeep Jain
Managing Director
We continue to deliver strong performance despite the industry headwinds of decreasing API prices and muted volume growth. With a sustained focus on R&D, we have been able to deliver robust growth. Achieving 1,000 DCGI approvals is a key milestone that stands out Akums from its peers, allowing Akums to offer margin accretive differentiated offerings. We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable and profitable growth in the years ahead.
Informational and educational content only. Not investment advice.